Novartis Suffers Three Clinical Setbacks in a Row, So Why Has Eli Lilly Avoided the Vortex? Sep 15, 2026 Life Science
Johnson & Johnson Advances Spin-Off and Sale in Parallel as Orthopedics Business Valued at Nearly $20 Billion Sep 11, 2026 Life Science
Broad Coverage or Concentrated Bets? Analyzing the Differences Between Healthcare Funds VHT and XPH Sep 11, 2026 Life Science
From $275 to $461, UnitedHealth Regains Confidence Through a Turnaround Script Sep 9, 2026 Life Science
AbbVie’s Diversification Bet Gradually Shows Results, While Pfizer Seeks a Second Takeoff Through Its GLP-1 and Oncology Pipelines Sep 5, 2026 Life Science
Pfizer Trades Below 10x P/E, But Does That Signal a Value Trap or a Long-Term Opportunity? Sep 4, 2026 Life Science
Eli Lilly Swallows Merida, Expanding Pipeline with Another Strategic Acquisition Sep 3, 2026 Life Science
Gene-Editing Pioneer CRISPR Therapeutics Worth a Bet Before Year-End? Two Catalysts Await Release Sep 3, 2026 Life Science
Uber Cuts 10% of Workforce in Pursuit of Change, Bets Billions on the Robotaxi Era Sep 2, 2026 Technology
GLP-1 Concept Stock Amylyx Soars 247% Year-to-Date: How Much Room Remains for Upside? Sep 2, 2026 Life Science
Novo Nordisk Faces Competitive Pressure and May Strengthen Its Weight-Loss Pipeline Through Acquisitions Sep 1, 2026 Life Science
Ark Invest Goes Against the Grain: Wood Bets on Nvidia and the Gene-Editing Arena Sep 1, 2026 Life Science
How to Choose Between Two Major Pharmaceutical Themed ETFs? Aug 28, 2026 Financial Service, Life Science
Clinical-Stage Biotechnology Company Biohaven Sees Dual Positive Developments During the Week Aug 28, 2026 Life Science
Billionaire Loads Up on Revolution Medicines, the Upside Could Be More Than 7% Aug 26, 2026 Life Science
